Group 1 - Thunder announced the completion of the acquisition of Hupu Sports platform for a total cash consideration of 500 million RMB [1][3] - The transaction involved an initial payment of 400 million RMB, with the remaining 100 million RMB to be paid in two equal installments over the next 24 months [3] Group 2 - Miniso is reportedly hiring JPMorgan and UBS to assist its TOP TOY brand in an IPO in Hong Kong [2] - Estun plans to issue overseas listed foreign shares (H shares) and list on the Hong Kong Stock Exchange, pending shareholder approval and regulatory approvals [2] Group 3 - Japan's Lawson will start selling rice balls made from 2023 rice in July, following government measures to address domestic rice shortages [6] - FamilyMart and 7-Eleven are also planning to sell reserve rice, with prices set at 360 yen per kilogram [6] Group 4 - The first domestically produced nine-valent HPV vaccine has been approved for market release in China, breaking a long-standing foreign monopoly [6] Group 5 - SpaceX CEO Elon Musk projected the company's revenue to exceed 15.5 billion USD this year, with significant contributions from NASA contracts and commercial space services [10][11] - SpaceX's revenue growth is primarily driven by its rocket launch services and Starlink business [10] Group 6 - The first commercial flight of China's domestically produced C919 aircraft was successfully completed, marking a significant milestone for the country's aviation industry [13] Group 7 - OpenAI announced that its paid enterprise users have increased from 2 million to 3 million, reflecting strong demand for its AI services [15] - OpenAI introduced new features for ChatGPT, including Connectors and Record Mode, aimed at enhancing integration into business workflows [15]

Group 1: Company Developments - Miniso has reportedly hired JPMorgan and UBS to assist its TOP TOY subsidiary in an IPO in Hong Kong [1] - Estun announced plans to issue overseas listed foreign shares (H shares) and list on the Hong Kong Stock Exchange, pending shareholder approval and regulatory approvals [1] - Xunlei has completed the acquisition of sports platform Hupu for a total consideration of 500 million yuan, with 400 million yuan paid upfront and the remaining 100 million yuan to be paid in two installments [2] Group 2: Market Trends and Consumer Products - Japanese convenience store Lawson will start selling rice balls made from 2023 rice in July, alongside unprocessed rice, as part of efforts to address domestic rice shortages [5] - The first domestically produced nine-valent HPV vaccine has been approved for sale in China, breaking a long-standing market monopoly [5] - The number of newborns in Japan is projected to fall below 700,000 for the first time in 2024, according to the Ministry of Health, Labour and Welfare [9] Group 3: Financial and Investment Activities - PingPong has received preliminary approval from the Central Bank of the UAE to become the first Chinese third-party payment institution to hold a payment license in the UAE [9] - Anner, known as the "first stock of children's clothing," is undergoing a change in control after its founders plan to transfer 13.03% of their shares, reducing their stake to 14.35% [9] - "Bocui Recycling" has announced additional investment in its Series B financing, accumulating over 100 million yuan for product development and overseas project collaboration [17] Group 4: Technology and Innovation - OpenAI has announced that its paid enterprise users have increased from 2 million to 3 million, reflecting significant growth in its AI services [13] - The humanoid robot company "Accelerated Evolution" has completed Series A financing led by Shenzhen Capital Group, with funds aimed at product upgrades and mass production [18] - The world robot football league "RoBoLeague" will kick off in Beijing, featuring AI-driven robots competing autonomously [14]

Group 1 - Xiaomi's founder Lei Jun commented on Apple's failure in car manufacturing, stating he does not know the reasons behind it, but acknowledged Apple as a great company that Xiaomi has learned from [3] - Bill Gates announced plans to spend most of his wealth on charitable causes in Africa over the next 20 years, with his foundation set to close by 2045 [3] Group 2 - Tesla is included in the 2025 rural electric vehicle initiative, with models like Model Y and Model 3 listed among 124 vehicles [8] - The first domestically produced nine-valent HPV vaccine has been approved for sale in China, developed by Wantai Biological Pharmacy [11] Group 3 - OpenAI reported a surge in paid enterprise users, reaching over 3 million, with projected revenue for the year at $12.7 billion [12] - NIO's CEO Li Bin reflected on the company's improved resilience compared to 2019, emphasizing the need for self-sufficiency in overcoming current challenges [13] Group 4 - Tesla's sales in Australia surged to 3,897 units in May, marking a 122.5% year-on-year increase for the Model Y, despite a 48.2% decline in total sales year-to-date [22] - The U.S. automotive market saw a significant drop in May sales, with a decline of approximately 160,000 units compared to April, attributed to preemptive purchases before price hikes [27] Group 5 - 58.com announced a $662 million acquisition of a pharmaceutical company, changing its controlling shareholder to Yao Jinbo [24] - The humanoid robot company Accelerated Evolution completed a Series A financing round, led by Shenzhen Capital Group, to enhance product development and mass production [24]

Core Viewpoint - The controversy surrounding the collagen products from Juzi Biotechnology has escalated into a public relations battle, primarily initiated by Dr. Hao Yu, a skincare influencer and former chemist, who accused the company of serious fraud regarding their recombinant collagen products [1][2][4]. Group 1: Key Players - Dr. Hao Yu, known as "Big Mouth Doctor," is a skincare influencer with millions of followers and a background in chemistry, having worked in cosmetic research for 19 years [2]. - Juzi Biotechnology is a biotech company specializing in the beauty industry, known for its recombinant collagen products, which have seen a significant market cap drop of over 100 billion, leaving it with a valuation of around 700 billion [2]. - Huaxi Biotechnology, a leading player in the A-share medical beauty sector, primarily focuses on hyaluronic acid products [3]. Group 2: Allegations and Responses - Dr. Hao Yu has accused Juzi Biotechnology of serious fraud, claiming that their recombinant collagen is undetectable, marking his second round of accusations [4][11]. - In response to the allegations, Juzi Biotechnology quickly issued a consumer notice denying all accusations of fraud and asserting that their products contain collagen levels above 0.1% [13][14]. - Juzi Biotechnology stated that they conducted multiple tests to confirm the collagen content and promised to release third-party testing results to alleviate consumer concerns [14]. Group 3: Testing Methods and Controversies - Dr. Hao Yu utilized High-Performance Liquid Chromatography (HPLC) for his testing, which he claims provides a more accurate measurement of collagen content compared to Juzi's methods [16][19]. - Juzi Biotechnology's testing method was revealed to be the Biuret test, which Dr. Hao Yu criticized for potentially yielding inflated results [32][36]. - The lack of standardized testing methods for recombinant collagen has been highlighted as a significant issue, leading to confusion and disputes over product efficacy [19][20]. Group 4: Market and Consumer Reactions - The public reaction has been mixed, with some consumers expressing outrage over potential deception, while others remain supportive of Juzi Biotechnology [45][48]. - The controversy coincided with a major shopping event, leading to increased consumer anxiety regarding the products [11]. - The involvement of various influencers and the emergence of coordinated online narratives have raised questions about the authenticity of public sentiment and potential manipulation [50][51]. Group 5: Regulatory and Industry Implications - The incident has drawn attention from regulatory bodies, with local market supervision authorities beginning to investigate the claims and counterclaims made by both parties [91]. - A high-profile seminar on testing methods for recombinant collagen was held, featuring prominent experts, indicating the industry's recognition of the need for clearer standards [57][60]. - The ongoing dispute may lead to broader discussions about product transparency and consumer protection within the beauty and biotech industries [84][92].

Market Overview - US stock indices closed mixed, with the Dow Jones down 0.22%, Nasdaq up 0.32%, and S&P 500 up 0.01% [2] - Major tech stocks showed varied performance, with Meta rising over 3% and Tesla falling over 3% [2] - The Nasdaq Golden Dragon China Index rose 2.04%, with notable gains in Chinese stocks like NIO and Alibaba [2] European Market - Major European indices closed higher, with Germany's DAX up 0.7%, France's CAC40 up 0.58%, and the UK's FTSE 100 up 0.16% [3] Urban Renewal Support - The central government plans to allocate over 20 billion yuan to support urban renewal actions in 20 cities, including Beijing and Tianjin, to address infrastructure shortcomings [4] AI Industry Development - The Ministry of Industry and Information Technology is focusing on promoting the AI industry and its integration into new industrialization, emphasizing a collaborative approach to strategy and policy implementation [5] New Power System Initiatives - The National Energy Administration announced pilot projects for new power system construction, focusing on various innovative technologies and models [6] Autonomous Driving Standards - A proposal for a mandatory national standard on safety requirements for intelligent connected vehicle driving assistance systems is under consideration [7] Virtual Asset Derivatives in Hong Kong - The Hong Kong Securities and Futures Commission is considering introducing virtual asset derivatives trading for professional investors, aiming to enhance market product offerings [8] HPV Vaccine Approval - China's first nine-valent HPV vaccine has been approved for market release, breaking a long-standing foreign monopoly [9] Quantum Communication Breakthrough - A Chinese research team has successfully completed module-level verification of a star-ground quantum direct communication system, marking a significant advancement in quantum communication technology [10] Economic Outlook - The Federal Reserve's latest Beige Book indicates a slight decline in US economic activity, with rising policy uncertainty and inflationary pressures affecting businesses and consumers [11] Tesla Sales Decline - Tesla's sales in China for May fell by 15% year-on-year, amidst a broader increase in the new energy vehicle market [26]

Core Viewpoint - The ongoing controversy surrounding Juzhi Biotechnology's alleged product fraud has escalated into a significant conflict within the medical aesthetics industry, involving major players like Huaxi Biotechnology and self-media influencer Gao Yu [1][3]. Group 1: Incident Development - The scandal began with allegations of Juzhi Biotechnology's collagen product being falsely represented, leading to a public dispute with Gao Yu, who claimed the product contained only 0.0177% of the required collagen, below the legal threshold of 0.1% [4][9]. - On May 30, the testing agency that supported Gao Yu retracted its report, which Juzhi interpreted as an apology, while still contesting the validity of Gao Yu's testing methods [2][3]. - The controversy has prompted other companies in the industry to begin testing their products, with over 100 samples submitted for testing by nine different companies [7]. Group 2: Industry Impact - The product in question, "Kefumei Human-Like Recombinant Collagen Essence," has been a core revenue driver for Juzhi, generating approximately 4.542 billion yuan in revenue in 2024, accounting for about 82% of the company's total revenue [9]. - Huaxi Biotechnology's involvement has intensified the situation, as they publicly supported Gao Yu and criticized the tactics used by Juzhi, suggesting a broader industry conflict [12][15]. - Following Huaxi's announcement, their stock rose by 6.94%, while Juzhi's stock fell by 4.69%, reflecting the market's reaction to the unfolding drama [16].

Core Viewpoint - The controversy surrounding the collagen content in the product "Kefumei" from Giant Biological has raised significant consumer and investor concerns, with ongoing debates about the accuracy of testing methods and results [1][10]. Group 1: Testing Results - Giant Biological confirmed that the "Kefumei Human-like Recombinant Collagen Essence" contains recombinant collagen, with content levels greater than 0.1% as per third-party testing [2][10]. - The testing utilized two methods: LC-MS/MS for qualitative analysis and the Biuret method for quantitative analysis, with results showing collagen content of 0.2%, 0.22%, and 0.2% across three batches [2][8]. - A subsequent test on one batch indicated a collagen content of 0.17%, confirming that the product meets the stated requirements [8][9]. Group 2: Consumer Concerns and Responses - The initial claim by beauty blogger "Big Mouth Doctor" suggested that the actual collagen content was only 0.0177%, leading to widespread skepticism about the product's integrity [10][11]. - Giant Biological emphasized that there is no misleading advertising and that the product has been properly tested, countering claims of "quietly delisting" the product due to sales issues [10][11]. - The company expressed concern over consumer anxiety caused by misinformation and reiterated its commitment to transparency and product integrity [10][11]. Group 3: Industry Reactions - Huaxi Biological publicly supported the claims made by "Big Mouth Doctor," indicating that they have conducted their own evaluations and testing of the product [11][14]. - Huaxi Biological criticized Giant Biological for alleged unethical marketing practices and indicated readiness to engage in a public discourse regarding product integrity [14][15].

Core Viewpoint - The beauty brand Proya is entering the medical aesthetics market with its first medical device product, a collagen patch aimed at post-surgery recovery, as it seeks new growth avenues amid slowing growth of its main brand [1][3][5]. Company Summary - Proya has launched its first medical device product, the medical collagen patch, which is designed for post-surgery skin care [1][3]. - The product is priced at 163 yuan after discount, down from 198 yuan, and is targeted at various skin recovery scenarios [3]. - Proya's main brand revenue growth is slowing, with a reported revenue of 85.81 billion yuan in 2024, showing less than 20% growth compared to previous years [5][6]. - The company aims to achieve a revenue scale exceeding 100 billion yuan in 2024 and has set a goal to enter the top ten global cosmetics companies within the next decade [6][9]. Industry Summary - The medical aesthetics market in China is rapidly expanding, with a market size of approximately 266.9 billion yuan in 2023, projected to exceed 700 billion yuan by 2031 [3][4]. - Other domestic beauty brands, such as Shanghai Jahwa and Beitaini, are also entering the medical aesthetics space, indicating a competitive landscape [4]. - The medical aesthetics sector is still in a phase of complete competition, with no dominant brands yet established, presenting opportunities for new entrants like Proya [4][9]. - Proya's entry into the medical aesthetics market is seen as a necessary strategy to maintain growth and compete with international brands, which have stronger brand positioning and marketing capabilities [9].

Core Viewpoint - The company, Juzi Biotechnology, clarified that its product, Kefu Mei, contains genuine recombinant collagen and denied allegations of false advertising and misleading consumers [1] Group 1 - Juzi Biotechnology announced the testing results of its recombinant collagen products through Kefu Mei's Weibo account [1] - The company stated that since April 16, the Kefu Mei Collagen Stick 2.0 has been launched, while the previous version, Kefu Mei Collagen Stick 1.0, has been sold out and is being phased out [1] - There is no truth to the rumors regarding the "quiet removal" of the Kefu Mei products, as some channels still have inventory available for sale [1]

华熙生物的下场无疑将"战况"再度升级，叠加此前，华熙生物炮轰"玻尿酸过时论"，华熙生物的此番下场战队，也被市场解读为是护肤成分市场中玻尿酸与 重组胶原蛋的路线之争。 出品｜搜狐财经 作者｜冯圆圆 端午假期期间，巨子生物产品造假风波再度升级。 6月1日晚间，华熙生物发文表示支持大嘴博士维护消费者权益；同时，已对大嘴博士发来的相关资料进行评估和第三方测试，且已得到结果。并表示，在其 公布结果之前，希望相关企业主动面对问题。 另一方面，巨子生物也在3小时后，发布了机构的道歉声明，同时表示对某上市公司的发言感到震惊又痛心。 一来一往，双方的发言均将矛头指向了对方。 可复美造假事件再升级 6月2日，知名大V大嘴博士再度发文"炮轰"巨子生物，剑指巨子生物对其合作的检测机构施压；同时表示，自己已联系不到当时负责检测的负责人。 （图片来源：大嘴博士颜究所） 大嘴博士的此番言论，再度将双方的"骂战"升级。 回顾时间线，5月24日，知名大V大嘴博士在微博发布了一则8分钟的视频，直指巨子生物旗下大单品可复美胶原蛋白精华的胶原蛋白含量造假。 （图片来源：大嘴博士微博） 据大嘴博士表示，巨子生物大单品可复美胶原蛋白精华中重组胶原蛋白的 ...